ATE532780T1 - Chinoline und ihre therapeutische verwendung - Google Patents

Chinoline und ihre therapeutische verwendung

Info

Publication number
ATE532780T1
ATE532780T1 AT08736891T AT08736891T ATE532780T1 AT E532780 T1 ATE532780 T1 AT E532780T1 AT 08736891 T AT08736891 T AT 08736891T AT 08736891 T AT08736891 T AT 08736891T AT E532780 T1 ATE532780 T1 AT E532780T1
Authority
AT
Austria
Prior art keywords
hydrogen
halogen
quinolines
therapeutic use
optionally substituted
Prior art date
Application number
AT08736891T
Other languages
English (en)
Inventor
John Montana
Harry Finch
George Hynd
Michael CRAMP
Rosa Arienzo
Neville Mclean
Original Assignee
Pulmagen Therapeutics Asthma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0706636A external-priority patent/GB0706636D0/en
Priority claimed from GB0724430A external-priority patent/GB0724430D0/en
Application filed by Pulmagen Therapeutics Asthma Ltd filed Critical Pulmagen Therapeutics Asthma Ltd
Application granted granted Critical
Publication of ATE532780T1 publication Critical patent/ATE532780T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
AT08736891T 2007-04-04 2008-04-03 Chinoline und ihre therapeutische verwendung ATE532780T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0706636A GB0706636D0 (en) 2007-04-04 2007-04-04 Receptor ligands
GB0724430A GB0724430D0 (en) 2007-12-14 2007-12-14 Receptor ligands
PCT/GB2008/001201 WO2008122784A1 (en) 2007-04-04 2008-04-03 Quinolines and their therapeutic use

Publications (1)

Publication Number Publication Date
ATE532780T1 true ATE532780T1 (de) 2011-11-15

Family

ID=39561800

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08736891T ATE532780T1 (de) 2007-04-04 2008-04-03 Chinoline und ihre therapeutische verwendung

Country Status (22)

Country Link
US (2) US8173812B2 (de)
EP (1) EP2139881B1 (de)
JP (1) JP5187862B2 (de)
CN (1) CN101679359B (de)
AT (1) ATE532780T1 (de)
AU (1) AU2008235282B2 (de)
BR (1) BRPI0809983A2 (de)
CA (1) CA2680682C (de)
CY (1) CY1112679T1 (de)
DK (1) DK2139881T3 (de)
EA (1) EA017093B1 (de)
ES (1) ES2375588T3 (de)
HK (1) HK1142604A1 (de)
HR (1) HRP20110987T1 (de)
IL (1) IL201013A (de)
MX (1) MX2009010461A (de)
NZ (1) NZ579659A (de)
PL (1) PL2139881T3 (de)
PT (1) PT2139881E (de)
SI (1) SI2139881T1 (de)
WO (1) WO2008122784A1 (de)
ZA (1) ZA200906384B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010461A (es) * 2007-04-04 2010-02-18 Argenta Oral Therapeutics Ltd Quinolinas y su usoterapeutico.
EP2229358B1 (de) 2007-12-14 2011-03-23 Pulmagen Therapeutics (Asthma) Limited Indole und ihre therapeutische verwendung
WO2012004722A1 (en) * 2010-07-05 2012-01-12 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (de) 2010-11-25 2012-05-30 Almirall, S.A. Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
RU2014129613A (ru) 2011-12-21 2016-02-10 Актелион Фармасьютиклз Лтд Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2
CN104428305A (zh) 2012-07-05 2015-03-18 埃科特莱茵药品有限公司 1-苯基-取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
EP2885285B1 (de) * 2012-07-17 2016-10-19 Boehringer Ingelheim International GmbH Pyrazolderivate zur hemmung einer leukotrienproduktion
DK3111224T3 (en) * 2014-02-24 2019-03-18 Ventana Med Syst Inc Quinonmethidanalog-signal gain
WO2022175829A1 (en) * 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58225065A (ja) * 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
TW297025B (de) * 1992-02-14 1997-02-01 Squibb & Sons Inc
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
BRPI0616452B8 (pt) * 2005-09-30 2021-05-25 Argenta Discovery Ltd quinolinas e seu uso terapêutico
MX2009010461A (es) * 2007-04-04 2010-02-18 Argenta Oral Therapeutics Ltd Quinolinas y su usoterapeutico.

Also Published As

Publication number Publication date
US8394830B2 (en) 2013-03-12
NZ579659A (en) 2012-01-12
US20120184579A1 (en) 2012-07-19
ES2375588T3 (es) 2012-03-02
PL2139881T3 (pl) 2012-04-30
DK2139881T3 (da) 2012-01-30
CN101679359B (zh) 2013-03-06
AU2008235282B2 (en) 2011-02-24
WO2008122784A1 (en) 2008-10-16
EA017093B1 (ru) 2012-09-28
AU2008235282A1 (en) 2008-10-16
EP2139881B1 (de) 2011-11-09
PT2139881E (pt) 2012-01-17
IL201013A0 (en) 2010-05-17
CY1112679T1 (el) 2016-02-10
US8173812B2 (en) 2012-05-08
HK1142604A1 (en) 2010-12-10
MX2009010461A (es) 2010-02-18
AU2008235282A8 (en) 2009-11-26
CA2680682C (en) 2015-05-26
US20100144787A1 (en) 2010-06-10
CN101679359A (zh) 2010-03-24
EP2139881A1 (de) 2010-01-06
IL201013A (en) 2015-01-29
BRPI0809983A2 (pt) 2014-10-14
JP2010523537A (ja) 2010-07-15
ZA200906384B (en) 2010-11-24
HRP20110987T1 (hr) 2012-01-31
JP5187862B2 (ja) 2013-04-24
SI2139881T1 (sl) 2012-05-31
EA200970911A1 (ru) 2010-04-30
CA2680682A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
ATE532780T1 (de) Chinoline und ihre therapeutische verwendung
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
ATE538099T1 (de) 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
EA201290260A1 (ru) Бензимидазол-имидазольные производные
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
RS54708B1 (en) ARYLETINYL DERIVATIVES
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX2009010909A (es) Derivados de ftalazino y su uso como medicamento para tratar el cancer.
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
MX2009009384A (es) Malonamidas como antagonistas de orexina.
NO20066049L (no) Substituerte tiazoleddiksyrer som CRTH2-ligandere
DE602006011725D1 (de) 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3-rezeptors
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
MX2010004498A (es) Derivados de ciclohexenoamida y su uso como antagonistas de trpv1.
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
UA87895C2 (en) Substituted 5-phenyl pyrimidines i in therapy
TN2014000519A1 (en) Pyrimidinone derivatives as antimalarial agents
PE20081893A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
MX2012008147A (es) Derivados de pirrazolopiridina.